Document:

EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(c) and Rule 24b-2 

AMENDMENT AGREEMENT No. 1 TO LICENCE AGREEMENT 

BETWEEN 
 CSL LIMITED

 ABN 99 051 588 348 

AND 
 ASLAN
Pharmaceuticals Pte Ltd 

 THIS AMENDMENT AGREEMENT No. 1 is made
the        day of                    2018. 

BETWEEN: 
  

	 	(1)	 CSL LIMITED incorporated and registered in Australia with ABN 99 051 588 348 of 45 Poplar Road,
Parkville, Victoria, Australia, 3052 (“CSL”) and 

  

	 	(2)	 ASLAN Pharmaceuticals Pte Ltd incorporated and registered in Singapore with company number
201007695N with registered office at 83 Clemenceau Avenue #12-03 UE Square, Singapore 239920 (“ASLAN”) 

(hereinafter collectively referred to as the “Parties” and individually as a “Party”) 

WHEREAS: 
  

	A.	 The Parties entered into a licence agreement on 12th May
2014 in relation to ASLAN’s development of Product to Clinical Proof of Concept and potential subsequent grant of commercialisation rights in the same to third parties (“Licence Agreement”). 

 

	B.	 The Parties wish to amend the Licence Agreement as set out below. 

THEREFORE the Parties do hereby agree as follows: 
  

	1.	 INTERPRETATION 

  

	1.1	 Unless otherwise provided in this Amendment Agreement, terms used in this Amendment Agreement shall have the
same meaning and construction as defined in the Licence Agreement. 

  

	2.	 AMENDMENTS TO THE LICENCE AGREEMENT 

 

	2.1	 In Recital (C) the word “asthma” shall be replaced with the word “atopic dermatitis”.

  

	2.2	 The definition of “CSL334” in clause 1.1 shall be deemed deleted in its entirety and replaced by the
following definition: 

 means CSL’s proprietary anti-IL13Rα1 monoclonal antibody known as CSL334 which has the
[...***...] set out in Schedule 2, and any [...***...] thereof, and includes any post translational modifications of such [...***...] References in this Agreement to ASLAN004 are to be read as references to CSL334. 

 

	2.3	 The definition of “Phase IIb Ready” in clause 1.1 shall be deemed deleted in its entirety and
replaced by the following definition: 

  
 ***
Confidential Treatment Requested 

  
 2 

 means Completion of clinical trials that support and immediately precede the initiation of a
randomized, double blind placebo controlled study to determine the efficacy of [...***...] 
  

	2.4	 The existing Section 9.1.1 of the Licence Agreement shall be deemed deleted in its entirety, and replaced
by the following new Section 9.1.1: 

 subject to the remainder of this clause, be on terms consistent with all of the
terms of this Agreement, including with respect to payments due to CSL. In relation to any confidentiality obligations in a Sub-license agreement which relate solely to information not subject to obligations
of confidence under a CSL Third Party Technology Agreement, ASLAN may agree for the duration of such obligations in the Sub-license agreement to be less than the duration specified in the first sentence of
Section 16.3, provided that such duration must in all cases be at least [...***...] from the date of disclosure of the relevant information by ASLAN; 
  

	2.5	 The existing Section 16.2.3(iii) of the Licence Agreement shall be deemed deleted in its entirety, and
replaced by the following new Section 16.2.3(iii): 

 ASLAN may disclose CSL’s Confidential Information to Third
Parties for the purposes of the Licensing Program on a need to know basis, and who must be bound by similar obligations of confidentiality as contained in this Agreement, provided, however, that in relation to any confidentiality obligations which
relate solely to information not subject to obligations of confidence under a CSL Third Party Technology Agreement, ASLAN may agree for the duration of such obligations to be less than the duration specified in the first sentence of
Section 16.3, provided further that such duration must in all cases be at least [...***...] from the date of disclosure of the relevant information by ASLAN; 
  

	2.6	 The existing Section 16.3 of the Licence Agreement shall be deemed deleted in its entirety, and replaced
by the following new Section 16.3: 

 Term of Confidentiality. The obligations of confidentiality set out in
this Section 16 shall apply from the Effective Date until [...***...] after the expiration or termination of this Agreement. In the case of information subject to obligations of confidence under a CSL Third Party Technology Agreement,
such information shall be treated as confidential in accordance with the terms of the relevant CSL Third Party Technology Agreement. 
  

	2.7	 At the end of Section 19.6.3 of the License Agreement, the word [...***...] at the end shall be
deleted and replaced with the following words: 

 [...***...] 

 
 *** Confidential Treatment Requested 

  
 3 

 [...***...] 
  

	2.8	 A new Section 3.3A shall be inserted immediately after Section 3.3 of the Agreement reading as
follows: 

  

	 	3.3A	 ASLAN shall prepare and submit an updated Development Program within [...***...] of the effective date of
the first amendment to this Agreement, reflecting the changes to this Agreement and the Master Plan implemented by that amendment. The updated Development Program will thereafter be further updated in accordance with Section 3.3.

  

	2.9	 The existing Schedule 1 – Master Plan of the License Agreement be replaced with Schedule 1 – Master
Plan attached to this Amendment Agreement No. 1. The development of Product to Clinical Proof of Concept shall be conducted in accordance with this Amendment Agreement. 

 

	2.10	 Save as expressly provided or varied herein, all other terms and conditions of the Licence Agreement, and all
rights and liabilities accruing before this Amendment Agreement comes into effect shall remain unaffected. 

  

	2.11	 This Amendment Agreement shall be read and take effect from the date it has been executed by both parties.

 [Signature page follows] 
  

*** Confidential Treatment Requested 

  
 4 

 IN WITNESS WHEREOF, the Parties have executed this Amendment Agreement in duplicate originals by
their duly authorised representative as of the date and year first above written. 
 Each person executing this Agreement on behalf of a Party represents
and warrants his/ her capacity and authority to do so. 
  

							
	 EXECUTED by CSL LIMITED 

ABN 99 051 588 348 by its duly authorised representatives
	  	 )
 )

)
 )
	  		  	  
 /s/ Andrew Nash

SVP Research
 September 18, 2018

 
 /s/ Fiona Mead

Company Secretary
 September 18, 2018

				
	EXECUTED by ASLAN Pharmaceuticals Pte Ltd	  	 )
 )

)
 )
	  		  	 /s/ Firth, Carl
 CEO

September 18, 2018

 SCHEDULE 1 

MASTER PLAN 

[...***...] 
  

*** Confidential Treatment Requested 

  
 6 

 [...***...] 

 
 *** Confidential Treatment Requested 

  
 7Exhibit

Exhibit 4.1

® SEE REVERSE SIDE INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE FOR CERTAIN DEFINITIONS CUSIP 08862E 10 9 THIS CERTIFIES THAT is the owner of C B Y O U FULLY PAID AND NON-ASSESSABLE COMMON SHARES, $0.0001 PAR VALUE, OF E N Q T U E I BEYOND MEAT, INC. R N S I I T G I N transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of this T E R D U certi*cate properly endorsed. This certi*cate is not valid until countersigned and registered by the Transfer Agent and Registrar. A S COMMON N D T R IN WITNESS WHEREOF, the said Corporation has caused this certi*cate to be signed by facsimile signatures of its duly C E O G M I authorized of*cers. S T P A E A U R N T E H Y Dated: D O : T R R I A Z A N E N D D S R S F E I E G R G N I A S A G T T U R E A N R R E CHIEF FINANCIAL OFFICER, TREASURER AND SECRETARY CHIEF EXECUTIVE OFFICER AND PRESIDENT TExhibit

Exhibit 4.6

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (the " 19 33 ACT"), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
PLAIN ENGLISH WARRANT AGREEMENT
This is a PLAIN ENGLISH WARRANT AGREEMENT dated August 10, 2012 by and between SAVAGE  RIVER, INC., a Delaware corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company.
The words "We", "Us", or "Our" refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words "You" or "Your" refers to the issuer, which is SAVAGE RIVER, INC., and not to any individual. The words "the Parties " refers to both TRIPLEPOINT CAPITAL LLC and SAVAGE RIVER, INC. This Plain English Warrant Agreement may be referred to as the "Warrant Agreement".
The Parties have entered into a Plain English Master Lease Agreement dated as of August 10, 2012, and related Software or Hardware Facility Schedules and Summary Schedules which are collectively referred to in this Warrant Agreement as the "Lease Agreement".
In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below:
	
							
	WARRANT INFORMATION

	Effective Date

August 10, 2012
	Warrant Number

0755-W-0l
	Lease Facility Schedules

Part 1: 0755-LE-0lH; 0755-LE-02S

	Warrant Coverage

Part 1: $130,000 (5% of
$2,600,000)
	Number of Shares

182,533, subject to adjustment as set forth in this Warrant Agreement
	Price Per Share

$0.7122, subject to adjustment as set forth in this Warrant Agreement
	Type of Stock

Series B Preferred Stock, subject to adjustment as set forth in this Warrant Agreement

	
			
	OUR CONTACT INFORMATION

	Name

TriplePoint Capital LLC
	Address For Notices

2755 Sand Hill Road, Ste. 150 Menlo Park, CA 94025
Tel: (650) 854-2090
Fax: (650) 854-1850
	Contact Person

Sajal Srivastava, COO
Tel: (650) 233-2102
Fax: (650) 854-1850
email: legal@triplepointcapital.com

	YOUR C ONTACT I NFORMA TION

	Customer Name

Savage River, Inc.
	Address For Notices

P.O. Box 2204
Manhattan Beach, CA 90267
	Contact Person

Brent Taylor, VP Corp. Development 
Tel: 310-702-6399
Fax: NIA
Email: btaylor@beyondmeat.com

1

	
	
	1.           WHAT YOU AGREE TO GRANT US

Part 1: You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, that number of fully paid and non­ assessable shares of Your Warrant Stock equal to One Hundred Thirty Thousand and No/100 Dollars ($130,000), divided by the Exercise Price, rounded to the nearest whole share.
The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4 hereof.
For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below:
"Exercise Price" means the lower of(a) $0.7122 (as adjusted for stock splits, stock dividends, reclassification and the like) and (b) the lowest per share price for which Your preferred stock is sold in the Next Round.
"Next Round" means the next bona fide round of equity financing in which You issue and sell shares of your preferred stock for aggregate gross cash proceeds of at least $1,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness) subsequent to the Effective Date.
"Warrant Stock" means (a) the class and series of Your preferred stock issued in the Next Round, if the lowest per share price for which such preferred stock is sold in the Next Round is less than $0.7122, or (b) in all other cases, Your Series B Preferred Stock. For avoidance of doubt, if this Warrant Agreement is exercised prior to the Next Round then this Warrant Agreement shall be exercisable for Your Series B Preferred Stock.
The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as part of the leased value and will be allocable to the Warrant Agreement and the original issue discount on the Lease Agreement shall be considered to be zero.
	
	
	2.           WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK.

The term of this Warrant Agreement and our right to purchase Warrant Stock will begin the Effective Date, and shall be available for the greater of (i) 7 years from the Effective Date or (ii) 5 years from the effective date of Your initial public offering.
	
	
	3.           HOW WE MAY PURCHASE YOUR WARRANT STOCK.

We may exercise Our purchase rights, in whole or in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I. Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any.
We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net Issuance method, You will issue Warrant Stock using the following formula:
	
		
	X=
	Y(A-B)

	 
	A

	
				
	Where:
	X=
	 
	the number of shares of Warrant Stock to be issued to Us.

	 
	Y=
	 
	the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.

	 
	A=
	 
	the fair market value of one share of Warrant Stock.

	 
	B=
	 
	the Exercise Price.

For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share of Warrant Stock:

2

If the exercise is in connection with the initial public offering of Your Common Stock, and if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial "Price to Public" specified in the final prospectus of the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise;
If this Warrant Agreement is exercised after, and not in connection with Your initial public offering, and:
		
	ð
	if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; or

		
	ð
	if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise.

If this Warrant Agreement is exercised prior to or after Your initial public offering, and:
		
	ð
	Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the­ counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold, from authorized but unissued shares), as determined in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other consolidation.

During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock.
If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement.
If at the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us.
	
	
	4.           WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE.

		
	ð
	If You are Acquired. If at any time: (i) there is a reorganization of Your stock (other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of the capital stock of You (each of the foregoing events are referred to as a "Merger Event"), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by Your Board of Directors) shall be made in the 

3

application of the provisions of this Warrant Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest extent possible.
		
	ð
	If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change.

		
	ð
	If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Warrant Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination.

		
	ð
	If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically provided for in the above paragraphs) of the Warrant Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of the Warrant Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of all shares of the Warrant Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.

		
	ð
	If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock. All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as may be amended from time to time. You will promptly provide Us with any restatement, amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with copies of any notices that You send to holders of the Warrant Stock with respect to any issuance of Your stock or other equity security to occur after the Effective Date (other than issuances of stock or equity securities pursuant to customary employee stock plans).

		
	ð
	If You Lease More Than the Commitment Amounts Under the Lease Agreement . If the total cost of equipment leased pursuant to the Lease Facility Schedules exceeds $2,600,000, We will have the right to purchase from You, at the Exercise Price (adjusted as set forth herein), an additional number of shares of Warrant Stock, which number shall be determined by (i) multiplying the amount by which the equipment cost financed under the Lease Facility Schedules exceeds $2,600,000 by 5%, and (ii) dividing the product by the Exercise Price per share referenced in Section 1 above; provided that the number of additional shares of Warrant Stock shall in no event exceed 351,025.

	
	
	5.           WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT.

Subject to the terms and conditions contained in Section 7 and subject to compliance with all applicable laws, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and all its rights; provided, however, that this Warrant Agreement may not be transferred unless the transferee makes all representations and warranties, and agrees to be bound by all the covenants set forth in Section 7. We agree not to transfer this Warrant Agreement to any entity which Your board of directors has determined in good faith to be a competitor of You. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in such transfer.
Each certificate representing (i) this Warrant Agreement, (ii) the Warrant Stock, (iii) the shares of Your Common Stock issued upon conversion of the Warrant Stock and (iv) any other securities issued in respect to the Warrant Stock or Common Stock issued upon conversion of the Warrant Stock upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable state securities laws):

4

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (the "1933 ACT"), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
	
	
	6.           REPRESENT ATIONS, WARRANTIES, AND COVENANTS FROM YOU.

		
	ð
	Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however, that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC.

		
	ð
	Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part and this Warrant Agreement is not inconsistent with Your Certificate of Incorporation or Bylaws, does not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound; however, (i) no stockholder approval has been obtained for the Next Round preferred stock (but such approval will be obtained in the event this Warrant Agreement becomes exercisable for Your Next Round preferred stock), (ii) the Company has not obtained the necessary corporate approval for the authorization of any shares of Next Round preferred stock (but such approval will be obtained in the event this Warrant Agreement becomes exercisable for Your Next Round preferred stock), and (iii) a sufficient number of shares of Next Round preferred stock has not been authorized under the Company's Certificate of Incorporation to provide for the issuance of such shares upon the exercise of this Warrant Agreement (but such authorization will be obtained in the event this Warrant Agreement becomes exercisable for Your Next Round preferred stock). This Warrant Agreement constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

		
	ð
	Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and state securities laws, which filings will be effective by the times required thereby.

		
	ð
	Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date:

Your authorized capital consists of (A) 28,182,533 shares of Common Stock, of which 3,947,222 shares of Common Stock are issued and outstanding, and (B) 15,082,533 shares of preferred stock, 5,000,000 of which are Series A Preferred Stock, of which 5,000,000 shares are issued and outstanding, and 10,082,533 of which are Series B Preferred Stock, of which 7,020,498 shares are issued and outstanding.
You have reserved 5,094,223 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 1,270,947 options have been granted. Except as otherwise provided in this Warrant Agreement and as noted above, there 

5

are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of Your capital stock or other of Your securities.
Except as set forth in Your Investors' Rights Agreement (as defined below), a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock.
		
	ð
	Other Commitments to Register Securities. Except as set forth in this Warrant Agreement and the Investors' Rights Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

		
	ð
	Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.

		
	ð
	Compliance with Rule 144. We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. Within ten (10) days of Our request, You agree to furnish Us, a written statement confirming Your compliance with the filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended.

		
	ð
	No Impairment. You agree not to, by amendment of Your Amended and Restated Certificate of Incorporation, by­ laws or other organizational or charter documents or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in carrying out of all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment. However, You shall not be deemed to have impaired Our rights if You amend Your Amended and Restated Certificate of Incorporation, or the holders of Your preferred stock waive their rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock; provided, however, that, notwithstanding the foregoing, You shall not impose any restrictions on the transferability or alienability of the Warrant Stock other than in effect as of the Effective Date without the express written consent of Us.

	
	
	7.           OUR REPRESENT ATIONS AND COVENANTS TO YOU.

		
	ð
	Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common Stock issuable upon conversion thereof will be acquired for investment purposes only and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation of the 1933 Act.

		
	ð
	Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7.

		
	ð
	Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. In no event will We make a disposition of any of Our rights to acquire Warrant Stock to any entity which Your board of directors has determined in good faith to be a competitor of 

6

you. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (I) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption.
		
	ð
	Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment.

		
	ð
	Risk of No Registration. We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of the 1934 Act (the "1934 Act"), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.

		
	ð
	Accredited Investor. We are an "accredited investor" within the meaning of the Securities and Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect.

		
	ð
	Confidentiality. All information (other than any such information contained in periodic reports filed by You with the Securities and Exchange Commission) disclosed by You to Us that is marked "Confidential" or that We have reason to believe is confidential shall be considered confidential for purposes of this Warrant Agreement. Except as set forth in the following sentence, We will not use or disclose to any third party, other than Our employees, agents, consultants, Affiliates, or advisors any confidential information without Your prior written consent. In handling any confidential information, We will exercise the same degree of care that We exercise for Our own proprietary information, but disclosure of information may be made (i) to Our subsidiaries or affiliates in connection with their business with You, so long as such subsidiaries or affiliates are bound by the same or similar confidentiality restrictions (ii) to prospective transferees (subject to Section 5) of the Warrant Agreement (provided, however, We shall obtain such prospective transferee's agreement of the terms of this provision and any purchaser, shall be agreeing to assume the obligations hereunder shall therefore agree to abide by the provisions hereof, including, without limitation, the provisions of this Section), (iii) as We deem necessary or appropriate to any bank, financial institution or other similar entity, provided, however, that such bank, financial institution or other similar entity agrees in writing to maintain the confidentiality of such information, (iv) to S&P, Moody's, Fitch and/or other ratings agency, as We deem necessary or appropriate, provided, however, that such financial institution or ratings agency shall be informed of the confidentiality of such, and it being understood such financial institution or ratings agency shall not provide any identifiable information of You, other than general aggregate information that does not identify You, to any party who is not subject to confidentiality restrictions similar to those set forth in this Agreement (v) as required by law, regulation, subpoena, or other order, (vi) as required in connection with Our examination or audit and (vii) as We consider necessary in exercising our righs under this Warrant Agreement. Confidential information does not include information that either: (a) is in the public domain or in Our possession when disclosed to Us, or becomes part of the public domain after disclosure to Us (other than as a result of disclosure by Us in violation of this paragraph); or (b) is disclosed to Us by a third party, if We do not know that the third party is prohibited from disclosing the information.

7

		
	ð
	Lock-Up. With respect to this Warrant, the Warrant Stock and shares of Common Stock issuable upon conversion of the Warrant Stock, We agree to be bound by the "Market Stand-Off Agreement " contained in Section 2.11 of the Investors ' Rights Agreement (as defined below).

	
	
	8.           NOTICES YOU AGREE TO PROVIDE US.

You agree to give Us at least ten (10) days prior written notice of the following events:
		
	ð
	If You Pay a Dividend or distribution declaration upon your stock.

		
	ð
	If You offer for subscription pro-rata to the existing shareholders additional stock or other rights.

		
	ð
	If You consummate a Merger Event.

		
	ð
	If You have an initial public offering.

		
	ð
	If You dissolve or liquidate.

All notices in this Section must set forth details of the event, how the event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment.
Timely Notice . Your failure to timely provide such notice required above shall entitle Us to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Us.
	
	
	9.           DOCUMENTS YOU WILL PROVIDE US.

Upon signing this Agreement You will provide Us with:
		
	ð
	Executed originals of this Agreement, and all other documents and instruments that We may reasonably require Secretary's

		
	ð
	certificate of incumbency and authority

		
	ð
	Certified copy of resolutions of Your board of directors approving this Warrant Agreement

		
	ð
	Certified copy of Certificate of Incorporation and by-laws as amended through the Effective Date Current

		
	ð
	Investors' Rights Agreement

So long as this Warrant Agreement is in effect, You shall provide Us with the following:
		
	ð
	Within ten (10) Business Days after the closing of any equity financing, or extension of an existing round of equity financing, occurring after the Effective Date, in which You issue preferred stock or other securities You will provide Us with copies of the fully executed equity financing documents, including without limitation the related stock purchase agreement, investors rights agreement, voting agreement, amended or restated certificates of incorporation, current capitalization table and other related documents.

		
	ð
	Within thirty (30) days after completion You shall provide Us with any 409A Valuation Reports or other similar reports prepared for You. Notwithstanding any term or condition contained in this Warrant Agreement to the contrary, Your failure to comply with this paragraph shall not constitute a default unless You have not provided the information requested within ten (10) days of Our request.

		
	ð
	After all obligations under the Lease Agreement have been finally paid in full, within thirty (30) days after the end of each quarter, You will provide Us with (1) an unaudited income statement, statement of cash flows, and an unaudited balance sheet prepared in accordance with GAAP accompanied by a report detailing any material contingencies, and (2) within one hundred eighty (180) days of the end of each fiscal year end, You will provide Us with audited financial statements accompanied by an audit report and an unqualified opinion of the independent certified public accountants. Notwithstanding any term or condition contained in this Warrant Agreement to the contrary, Your failure to comply with this paragraph shall not constitute a default unless You have not provided the information requested within ten (10) days of Our request.

8

		
	ð
	You shall submit to Us any other documents and other information that We may reasonably request from time to time and are necessary to implement the provisions and purposes of this Warrant Agreement; provided that highly confidential and privileged information may be redacted from any such information.

	
	
	10.           REGISTRATION RIGHTS UNDER THE 1933 ACT.

The shares of Your common stock into which the Warrant Stock is convertible shall have "piggyback " registration rights as set forth in the Amended and Restated Investors' Rights Agreement, dated as of January 31, 2012, (as amended, the "Investors' Rights Agreement"). The provisions set forth in Your Investors' Rights Agreement relating to such "piggyback" registration rights in effect as of the date of this Warrant Agreement may not be amended, modified or waived without Our prior written consent unless such amendment, modification or waiver affects the rights associated with the shares of common stock into which the Warrant Stock is convertible in the same manner as such amendment, modification, or waiver affects the rights associated with a like number of shares of the same series and class of stock as the Warrant Stock.
	
	
	11.           OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY.

Effective Date . This Warrant Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties.
Attorney' s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party shall be entitled to attorneys' fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement.
Governing Law . This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws .
Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, "CLAIMS") ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIYER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE ("REFERENCE"). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES 

9

ACKNOWLEDGE THAT TPE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement.
Counter parts. This Warrant Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Notices. Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (I) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party.
Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Agreement.
Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall survive the execution and delivery of this Warrant Agreement.
Severability. In the event any one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the Parties underlying the invalid, illegal or unenforceable provision.
Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter.
Amendments . Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties.
Lost Warrants or Stock Certificates . You covenant to Us that, upon receipt of evidence reasonably satisfactory to You of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate.
Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or receive dividends or be deemed the holder of Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.
Signatures. This Warrant Agreement may be executed and delivered by facsimile or transmitted electronically in Portable Document Format ("PDF") and, upon such delivery, the facsimile or PDF signature, as applicable, will be deemed to have the same effect as if the original signature had been delivered to the other party.
(Signature Page to Follow)

10

IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.
	
			
	You:
	SAVAGE RIVER, INC.

	 
	 
	 

	Signature:
	/s/ Ethan Brown

	 
	 
	 

	Print Name:
	Ethan Brown

	 
	 
	 

	Title:
	Pres & CEO

	 
	 
	 

	 
	 
	 

	Us:
	TRIPLEPOINT CAPITAL LLC

	 
	 
	 

	Signature:
	 

	 
	 
	 

	Print Name:
	 

	 
	 
	 

	Title:
	 

[SIGNATURE PAGE TO WARRANT AGREEMENT 0755 -W-01]

11

IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.
	
			
	You:
	SAVAGE RIVER, INC

	 
	 
	 

	Signature:
	 

	 
	 
	 

	Print Name:
	 

	 
	 
	 

	Title:
	 

	 
	 
	 

	Us:
	TRIPLEPOINT CAPITAL LLC

	 
	 
	 

	Signature:
	/s/ Sajal Srivastava

	 
	 
	 

	Print Name:
	Sajal Srivastava

	 
	 
	 

	Title:
	COO

[SIGNATURE PAGE TO WARRANT AGREEMENT 0755-W-01]

12

EXHIBIT I 
NOTICE OF EXERCISE
To:    [    ]
		
	1.
	We hereby elect to purchase [            ] shares of the Series [            ] Preferred Stock of [            ], pursuant to the terms of the Plain English Warrant Agreement dated the[     ] day of [        ], [20_] (the "Plain English Warrant Agreement") between You and Us, We hereby tender here payment of the purchase price for such shares in  full,  together with all applicable transfer taxes, if any.

2.Method of Exercise (Please initial the applicable blank)
		
	a.
	    The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

		
	b.
	    The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement.

		
	3.
	In exercising Our rights to purchase the Series [        ] Preferred Stock of [                           ]., We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the Plain English Warrant Agreement.

Please issue a certificate or certificates representing these purchased shares of Series [            ] Preferred Stock in Our name or in such other name as is specified below.
	
		
	 

	(Name)
	 

	 
	 

	 

	(Address)
	 

	
			
	US:                   TRIPLEPOINT CAPITAL LLC

	 
	 
	 

	By:
	 

	 
	 
	 

	Title:
	 

	 
	 
	 

	Date:
	 

12

EXHIBIT II 
ACKNOWLEDGMENT OF EXERCISE
[                                      ] hereby acknowledges receipt of the "Notice of Exercise" from TRIPLEPOINT CAPITAL LLC, to purchase [             ] shares of the Series [     ] Preferred Stock of [             ] pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [         ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement.
	
				
	YOU:
	 
	SAVAGE RIVER, INC.

	 
	 
	 
	 

	 
	 
	By:
	 

	 
	 
	 
	 

	 
	 
	Title:
	 

	 
	 
	 
	 

	 
	 
	Date:
	 

13

EXHIBIT III 
TRANSFER NOTICE
FOR VALUE RECEIVED, the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to
	
				
	 
	 

	(Please Print)
	 
	 
	 

	 
	 
	 
	 

	Whose Address is
	 

	 
	 
	 
	 

	 

	 
	 
	 
	 

	Dated:
	 
	 

	 
	 
	 
	 

	Holder's Signature:
	 
	 

	 
	 
	 
	 

	Holder's Address:
	 
	 

By its signature below, the undersigned Transferee hereby:
(1)acknowledges that it has reviewed the Plain English Warrant Agreement and agrees to be bound by and to comply with all terms, conditions and covenants therein, including, without limitation, the confidentiality paragraph of Section 7 thereof; and
(2)makes all of the representations and warranties contained in Section 7 to You as of the date hereof.
	
			
	Transferee's Signature:
	 

	 
	 
	 

	Transferee's Address:
	 

	 
	 
	 

	Signature Guaranteed:
	 

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain English Warrant Agreement.

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]